Logo Logo

Publications by Al-Batran, Salah-Eddin

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Lordick, Florian; Al-Batran, Salah-Eddin; Dietel, Manfred; Gaiser, Timo; Hofheinz, Ralf-Dieter; Kirchner, Thomas; Kreipe, Hans H.; Lorenzen, Sylvie; Möhler, Markus; Quaas, Alexander; Röcken, Christoph; Rüschoff, Josef; Tannapfel, Andrea; Thuss-Patience, Peter; Baretton, Gustavo (2017): HER2 testing in gastric cancer: results of a German expert meeting. In: Journal of Cancer Research and Clinical Oncology, Vol. 143, No. 5: pp. 835-841

Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje; Heinemann, Volker (2017): Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). In: International Journal of Cancer, Vol. 140, No. 8: pp. 1918-1925

Harbeck, Nadia; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard Jörg; Waldenmaier, Dirk; Dorn, Julia; Warm, Mathias; Scholz, Michael; Untch, Michael; Wit, Maike de; Barinoff, Jana; Lück, Hans-Joachim; Harter, Philipp; Augustin, Doris; Harnett, Paul; Beckmann, Matthias W.; Al-Batran, Salah-Eddin (2017): A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. In: Breast Cancer Research and Treatment, Vol. 161, No. 1: pp. 63-72

Joensuu, Heikki; Wardelmann, Eva; Sihto, Harri; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Cameron, Silke; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Nilsson, Bengt; Kallio, Raija; Junnila, Jouni; Vehtari, Aki; Reichardt, Peter (2017): Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial. In: Jama Oncology, Vol. 3, No. 5: pp. 602-609

Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Ramadori, Giuliano; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Sihto, Harri; Bono, Petri; Kallio, Raija; Junnila, Jouni; Alvegård, Thor; Reichardt, Peter (2016): Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. In: Journal of Clinical Oncology, Vol. 34, No. 3: 244-U99

Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas; Heinemann, Volker (2016): Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab). In: Journal of Clinical Oncology, Vol. 34, No. 4

Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas; Heinemann, Volker (2016): FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. In: Lancet Oncology, Vol. 17, No. 10: pp. 1426-1434

This list was generated on Thu Jul 18 05:56:52 2019 CEST.